Evaluation of Prucalopride in Male Subjects With Chronic Constipation.

A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Prucalopride in Male Subjects With Chronic Constipation

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01147926

Enrollment

374

Registered

2010-06-22

Start date

2010-09-23

Completion date

2013-10-25

Last updated

2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male Subjects With Chronic Constipation

Keywords

Constipation, Male

Brief summary

This is a multi-centre, randomised, parallel-group, double-blind, placebo-controlled phase III trial to evaluate the efficacy of prucalopride versus placebo over 12 weeks of treatment in male subjects with chronic constipation. Furthermore the safety, tolerability, effect on quality of life and effect on symptoms of prucalopride will be assessed.

Detailed description

In this phase III trial subjects will be screened and enter a 2-week run-in period (or a 3-week run-in period if the subject is using agents that influence bowel habit) during which the presence of constipation will be confirmed \[the subject will complete an electronic daily diary (e-diary)\]. At the start of run-in, all existing laxative medication will be withdrawn and subjects will be instructed not to change their diet or lifestyle during the trial. Subjects will be allowed to take a laxative \[Dulcolax (bisacodyl)\] as rescue medication during the trial, but only if they have not had a bowel movement (BM) for 3 or more consecutive days. An enema can only be used after unsuccessful use of Dulcolax (bisacodyl). No Dulcolax (bisacodyl) should be taken or enemas used between 48 hours before and 48 hours after the first intake of study medication. After the run-in subjects will be randomly assigned to placebo or prucalopride in an equal ratio (1:1) if the subject fulfils the constipation criteria for inclusion. Randomisation will be stratified by country and by the average number of complete bowel movements (CBM) during run-in: 0 CBM/week and \> 0 CBM/week. Adult subjects (i.e. subjects ≥18 to \<65 years of age) will take 2 mg prucalopride or matching placebo once daily before breakfast during the entire 12-week treatment period. Elderly subjects (i.e. subjects ≥65 years of age) will start at a dose of 1 mg prucalopride or matching placebo once daily before breakfast. In case of insufficient response, defined as an average of \<3 spontaneous complete bowel movements (SCBM)/week during the preceding 2 weeks of treatment (i.e. since the previous visit) at Week 2 or Week 4, the daily dose has to be increased to 2 mg (or matching placebo). Once the dose is increased to 2 mg once daily the subject will stay on this dose for the remainder of the trial. After Week 4 (Visit 4) no changes in dose are allowed anymore.

Interventions

DRUGPlacebo

Placebo matched to Prucalopride tablet orally once daily.

DRUGPrucalopride

Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subject is a male out-patient ≥18 years of age (no upper age limit). 2. Subject has a history of constipation. The subject reports an average of ≤ 2 SBM/week that result in a feeling of complete evacuation (SCBM) and one or more of the following for at least 6 months before the selection visit: 1. Very hard (little balls) and/or hard stools for at least a quarter of the stools; 2. Sensation of incomplete evacuation following for at least a quarter of the stools; 3. Straining at defecation for at least a quarter of the time. This includes subjects who never have SBMs. The above criteria are only applicable for SBMs, i.e. BMs not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema. 3. Subject agrees to stop his current laxative treatment and is willing to use rescue medication according to the rescue rule \[Dulcolax® (bisacodyl)/enemas\] 4. Subject's constipation is chronic. 5. Subject is able and willing to complete the questionnaires (if a validated version in the language of the subject is available) and the e-diary. 6. Subject voluntarily signs the written Informed Consent Form (ICF) in accordance with the regional laws/regulations, prior to the first trial-related activity. 7. Subject is willing to adhere to all trial requirements (amongst others colonoscopy/sigmoidoscopy, if required).

Exclusion criteria

1. Subjects in whom constipation is thought to be drug-induced. 2. Subjects using any disallowed medication 3. Subjects suffering from secondary causes of chronic constipation, such as: Endocrine disorders, e.g. hypopituitarism, hypothyroidism, hypercalcaemia, pseudohypoparathyroidism, pheochromocytoma or glucagon-producing tumours, unless these are controlled by appropriate medical therapy. Subjects with insulin-dependent diabetes mellitus should always be excluded, also if the subjects are under appropriate medical therapy; Metabolic disorders (e.g. porphyria, uraemia, hypokalaemia or amyloid neuropathy, unless these are controlled by appropriate medical therapy); Neurological disorders (e.g. Parkinson's disease, cerebral tumours, cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis, hypoganglionosis, hyperganglionosis, autonomic neuropathy or neuropathy due to chemotherapy, spinal cord injury, Chaga's disease, major depression); Surgery. Subjects with insulin-dependent diabetes mellitus should always be excluded, irrespective of whether the constipation started prior to or after the onset of diabetes. 4. Subjects with a significant history of cancer (i.e. less than a 5-year disease-free survival). 5. Subjects with intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic megacolon/megarectum. Results of an endoscopy or radiologic bowel evaluation is required to rule out polyps, cancer, stricture or other structural or organic disease: 1. For patients ≤ 50 years: a flexible sigmoidoscopy or colonoscopy after the onset of constipation symptoms and within the previous 5 years; 2. For patients \> 50 years: a flexible sigmoidoscopy /double contrast barium enema or colonoscopy after the onset of constipation symptoms and within the previous 5 years. 3. For subjects, regardless of age, even if results of this test are available within the previous 5 years but if the patient has alarm symptoms such as anemia, weight loss, heme positive stool, or rectal bleeding: a flexible sigmoidoscopy and double contrast barium enema or colonoscopy is needed after the onset of symptoms. 4. If abnormalities have been detected during the sigmoidoscopy or colonoscopy e.g., because of polyps, the subject can be included in the trial if the polyps were removed. If clinically indicated, a repeat colonoscopy/sigmoidoscopy needs to be performed at latest within one week after the screening visit. If no barium enema with flexible sigmoidoscopy or a colonoscopic examination has been performed within the period as described above, the assessment is to be scheduled on the screening visit or within the week following screening. When it is clinically indicated that a repeat colonoscopy/sigmoidoscopy is needed to confirm results of a colonoscopy/sigmoidoscopy performed after the screening visit, the subject should be a screen failure. 6. Subjects with known serious illness: clinically significant cardiac, vascular, liver, pulmonary, or psychiatric disorders (as evaluated by the Investigator). 7. Subjects with any condition that in the opinion of the Investigator would complicate or compromise the trial or the well-being of the subject or evidence of clinically relevant pathology that could interfere with the trial results or put the subject's safety at risk. 8. Subjects known to have human immunodeficiency virus (HIV) infection or AIDS, hepatitis B or hepatitis C. 9. Subjects with impaired renal function, i.e. serum creatinine concentration \>180 μmol/l or calculated creatinine clearance ≤30 ml/min, including subjects requiring dialysis. 10. Subjects with clinically significant abnormalities of haematology, urinalysis, or blood chemistry as determined by the Investigator. If the results of the haematology, biochemistry or urinalysis tests are not within the laboratory's reference ranges, the subject can be included only on the condition that the Investigator judges that the deviations are not clinically significant. This should be clearly recorded in the electronic Case Report Form (e-CRF). 11. Subjects with a known history of alcohol or drug abuse in the previous 6 months. 12. Subjects with lactose intolerance for whom it is expected that low doses of lactose can lead to diarrhoea, or a known allergy to ingredients or excipients of the trial medication. 13. Subjects who received an investigational drug in the 30 days preceding the run-in period of the trial. 14. Subjects who previously used prucalopride.

Design outcomes

Primary

Measure	Time frame	Description
The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week	Over 12 week treatment period	Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.

Secondary

Measure	Time frame	Description
Percentage of Subjects With an Increase of at Least 1 SCBM Per Week	Over 12 week treatment period	—
SCBM Per Week	Over 12 week treatment period	—
Percent SBM With a Consistency of Normal and Hard/Very Hard	Over 12 week treatment period	Consistency measured using the 7-point Bristol scale where 1-2 indicate constipation (=hard/very hard), 3-4 are ideal stools (=normal), and 5-7 tending toward diarrhea.
Percent SCBM With No Straining and Severe/Very Severe Straining	Over 12 week treatment period	Straining was evaluated on a 5-point scale (0=none, 1=mild, 2=moderate, 3=severe, or 4=very severe)
Percent SBM With Sensation of Complete Evacuation	Over 12 week treatment period	—
Time to First SCBM After Investigational Product Intake on Day 1	Day 1	—
Percentage of Subjects With an Average Weekly Frequency of at Least 3 SCBM Per Week and an Increase of ≥ 1 SCBM Per Week for ≥ 75% of the 12-week Treatment Period and ≥ 75% of the Last Third of the 12-week Treatment Period	Over 12 week treatment period	—
Days With Rescue Medication Taken Per Week	Over 12 week treatment period	—
Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation - Symptom (PAC-SYM) Questionnaire Total Score at Final On Treatment Assessment	Over 12 week treatment period	The PAC-SYM is a validated 12-item questionnaire for the evaluation of severity of symptoms of constipation in subjects with constipation. Items are rated on a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe. Total score ranges from 0 to 48. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-SYM total score was considered clinically meaningful.
Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Total Score at Final On Treatment Assessment	Over 12 week treatment period	The PAC-QOL is a validated 28-item questionnaire for the evaluation of quality of life in subjects with constipation. Items are rated on a 5-point Likert scale: 0=not at all/none of the time, 1=a little bit/a little bit of the time, 2=moderately/some of the time, 3=quite a bit/most of the time, 4=extremely/all of the time. Total score ranges from 0-112. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-QOL total score was considered clinically meaningful.
Percent of Subjects on the Subject Global Evaluation on Severity of Constipation Score Rating Constipation as Severe to Very Severe at Final On-Treatment Assessment	Over 12 week treatment period	Subject was asked to rate the severity of his constipation using a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe
Percent of Subjects on the Subject Global Evaluation on Efficacy of Treatment Score Rating Treatment as Quite a Bit to Extremely Effective at Final On-Treatment Assessment	Over 12 week treatment period	The subject was asked to rate his global evaluation of the efficacy of treatment using the following 5-point scale: 0=not at all effective 1=a little bit effective 2=moderately effective 3=quite a bit effective 4=extremely effective.
Bisacodyl Tablets Taken Per Week	Over 12 week treatment period	—

Countries

Belgium, Bulgaria, Czechia, Denmark, France, Germany, Netherlands, Poland, Romania, United Kingdom

Participant flow

Participants by arm

Arm	Count
PLACEBO Placebo matched to Prucalopride tablet orally once daily.	186
PRUCALOPRIDE Prucalopride 2 mg tablet orally once daily for subjects ≥18 to \<65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.	184
Total	370

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Adverse Event	7	6
Overall Study	Colonoscopy result	0	1
Overall Study	Lack of Efficacy	1	0
Overall Study	Lost to Follow-up	0	2
Overall Study	Principal investigator left hospital	1	3
Overall Study	Selection criteria not met	3	1
Overall Study	Sponsor's Decision	0	1
Overall Study	Subject Non-Compliant	5	4
Overall Study	Subject Withdrew Consent	9	10
Overall Study	Too busy, no time for study	1	0
Overall Study	Went on holiday	0	1

Baseline characteristics

Characteristic	PLACEBO	PRUCALOPRIDE	Total
Age, Continuous	58.5 Years STANDARD_DEVIATION 16.28	58.4 Years STANDARD_DEVIATION 17.57	58.5 Years STANDARD_DEVIATION 16.91
Age, Customized 75 years and above	32 Participants	37 Participants	69 Participants
Age, Customized Between 65 and 75 years	39 Participants	43 Participants	82 Participants
Age, Customized Less than 65 years	115 Participants	104 Participants	219 Participants
Region of Enrollment BELGIUM	10 Participants	10 Participants	20 Participants
Region of Enrollment BULGARIA	9 Participants	9 Participants	18 Participants
Region of Enrollment CZECH REPUBLIC	15 Participants	14 Participants	29 Participants
Region of Enrollment DENMARK	21 Participants	19 Participants	40 Participants
Region of Enrollment FRANCE	20 Participants	21 Participants	41 Participants
Region of Enrollment GERMANY	11 Participants	10 Participants	21 Participants
Region of Enrollment NETHERLANDS	5 Participants	5 Participants	10 Participants
Region of Enrollment POLAND	28 Participants	26 Participants	54 Participants
Region of Enrollment ROMANIA	57 Participants	56 Participants	113 Participants
Region of Enrollment UNITED KINGDOM	10 Participants	14 Participants	24 Participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants
Sex: Female, Male Male	186 Participants	184 Participants	370 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	21 / 186	37 / 184
serious Total, serious adverse events	4 / 186	1 / 184

Outcome results

Primary

The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week

Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.